Effective childhood cancer treatment: The impact of large scale clinical trials in Germany and Austria
2013; Wiley; Volume: 60; Issue: 10 Linguagem: Inglês
10.1002/pbc.24598
ISSN1545-5017
AutoresClaudia Rössig, Heribert Juergens, Martin Schrappe, Anja Moericke, G. Henze, Arend von Stackelberg, Dirk Reinhardt, Birgit Burkhardt, Wilhelm Woessmann, M Zimmermann, Helmut Gadner, Georg Mann, G. Schellong, Christine Mauz‐Koerholz, Uta Dirksen, Stefan Bielack, Frank Berthold, Norbert Graf, Stefan Rutkowski, Gabriele Calaminus, Peter Kaatsch, Ursula Creutzig,
Tópico(s)Acute Lymphoblastic Leukemia research
ResumoIn Germany and Austria, more than 90% of pediatric cancer patients are enrolled into nationwide disease-specific first-line clinical trials or interim registries. Essential components are a pediatric cancer registry and centralized reference laboratories, imaging review, and tumor board assistance. The five-year overall survival rate in countries where such infrastructures are established has improved from 80% since 1995. Today, treatment intensity is tailored to the individual patient's risk to provide the highest chances of survival while minimizing deleterious late effects. Multicenter clinical trials are internationalized and serve as platforms for further improvements by novel drugs and biologicals.
Referência(s)